依达拉奉治疗急性脑梗死154例临床疗效观察

A clinical analysis for the therapeutic effect of edaravone in 154 cases of acute cerebral infarction

目的脑梗死是严重威胁人类健康的常见疾病,本研究分别采用依达拉奉和常规方案治疗急性脑梗死154例,对急性脑梗死的治疗效果进行对比分析。方法将154例发病在48h以内的急性脑梗死患者随机分为依达拉奉治疗组76例和常规治疗对照组78例,治疗组采用依达拉奉30mg静脉滴注,2次/d,常规治疗对照组采用维脑路通和阿司匹林等治疗方法,疗程共14d。以神经功能缺损评分(european stroke scale,ESS)和日常生活能力评分(activities of daily living,ADL)的增分率来判断、比较不同治疗方案的疗效。结果依达拉奉组和对照组患者在治疗前的一般情况差异无显著性(P>0.05),14d治疗结束后,依达拉奉治疗组和常规治疗对照组的ESS增分率分别为(50.39±23.37)和(23.52±22.71);ADL增分率分别为(48.76±21.32)和(26.72±21.73)。依达拉奉的运用显著提高了对急性脑梗死的治疗效果(P<0.01)。结论依达拉奉能安全有效地治疗急性脑梗死。

[ Objective ] Acute cerebral infarction （ACI） represents a common clinical problem with high morbidity and lethality. The aim of this study is to investigate the therapeutic effect of Edaravone on ACI. [Methods] 154 cases of acute cerebral infarction （ACI）, enrolled within 48 h of onset and completed this study, were randomly divided into the edaravone group （76 Cases） and control group （78 cases）. All the patients were treated with Troxerutin and Aspirin for 14 days, while the patients in edaravone group received additional edaravone infusion at a dose of 30 mg, twice a day. The improvement of patients＇ neurologic impairment （European stroke scale, ESS） and daily viabili- ty （activities of daily living, ADL） was assessed respectively. [Results] Edaravone treatment group and control group did not differ significantly in terms of the general state of the subjects＇ health at entry. The improvement rates of ESS in the groups of Edaravone and control were （50.39±23.37） and （23.52±22.71）, respectively. The improvement rates of ADL in the groups of Edaravone and control were （48.76±21.32） and （26.72±21.73）, respectively. The employment of edaravone in the treatment prescription significantly improved the therapeutic effect for ACI （P 〈0.01 ）. [ Conclusion] Edaravone can treat ACI effectively and safely without severe complication.